Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

04. Mai 2018 08:00 ET | Quelle: Lexicon Pharmaceuticals, Inc.

Lexicon Pharmaceuticals Announces Publication of New XERMELO® (Telotristat Ethyl) Data in Clinical Therapeutics

Significant Dose-Dependent Effects on Changes in Weight Gain and Biochemical and Metabolic Parameters Improvements in Diarrhea Severity and Nutritional Status THE WOODLANDS, Texas, May 04, 2018 ...
03. Mai 2018 07:00 ET | Quelle: Lexicon Pharmaceuticals, Inc.

Lexicon Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides a Business Update

XERMELO® (telotristat ethyl) Quarterly U.S. Net Sales of $5.4 Million Filings Submitted for Regulatory Approval of Sotagliflozin in Type 1 Diabetes THE WOODLANDS, Texas, May 03, 2018 (GLOBE...
01. Mai 2018 07:00 ET | Quelle: Lexicon Pharmaceuticals, Inc.

Lexicon Pharmaceuticals to Present at Upcoming Investor Conference

THE WOODLANDS, Texas, May 01, 2018 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq:LXRX) today announced that Lonnel Coats, President and Chief Executive Officer, will present at the...
26. April 2018 07:00 ET | Quelle: Lexicon Pharmaceuticals, Inc.

Lexicon Pharmaceuticals to Host First Quarter 2018 Financial Results Conference Call and Webcast on May 3, 2018

THE WOODLANDS, Texas, April 26, 2018 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq:LXRX), will release its first quarter 2018 financial results on Thursday, May 3, 2018 before market...
03. April 2018 07:00 ET | Quelle: Lexicon Pharmaceuticals, Inc.

Lexicon Pharmaceuticals to Highlight Pipeline Progress at R&d Day on April 10, 2018

THE WOODLANDS, Texas, April 03, 2018 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq:LXRX), announced today that it will host its 2018 Research & Development (R&D) Day on Tuesday,...
29. März 2018 01:00 ET | Quelle: Lexicon Pharmaceuticals, Inc.

Lexicon Pharmaceuticals Announces EMA Acceptance of Marketing Authorization Application (MAA) for Sotagliflozin to Treat Adults With Type 1 Diabetes

THE WOODLANDS, Texas, March 29, 2018 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq:LXRX), today announced that the European Medicines Agency (EMA) has accepted the Marketing...
26. März 2018 07:00 ET | Quelle: Lexicon Pharmaceuticals, Inc.

Lexicon Pharmaceuticals Announces Regulatory Submissions for Sotagliflozin to Treat Adults With Type 1 Diabetes

New Drug Application Submitted to U.S. Food and Drug Administration Marketing Authorization Application Submitted to European Medicines Agency THE WOODLANDS, Texas, March 26, 2018 (GLOBE NEWSWIRE)...
28. Februar 2018 07:00 ET | Quelle: Lexicon Pharmaceuticals, Inc.

Lexicon Pharmaceuticals Announces Poster Presentation at the 15th Annual ENETS Conference

THE WOODLANDS, Texas, Feb. 28, 2018 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq:LXRX), announced today that data from a poster highlighting XERMELO® (telotristat ethyl) will be...
27. Februar 2018 16:30 ET | Quelle: Lexicon Pharmaceuticals, Inc.

Lexicon Pharmaceuticals to Present at Upcoming Investor Conferences

THE WOODLANDS, Texas, Feb. 27, 2018 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq:LXRX) today announced that Jeffrey L. Wade, J.D., Executive Vice President, Corporate and Administrative...
22. Februar 2018 07:00 ET | Quelle: Lexicon Pharmaceuticals, Inc.

Lexicon Pharmaceuticals Reports Fourth Quarter and Full-Year 2017 Financial Results and Provides a Business Update

XERMELO® (telotristat ethyl) U.S. Net Sales Since March 2017 Launch Reach $15.1 Million Regulatory Filings for Sotagliflozin in Patients with Type 1 Diabetes Expected in First Quarter of 2018 THE...

Vorherige Seite